The Commission had concerns that the acquisition, as initially notified, would have eliminated a credible future competitor of Bard, and so was likely to reduce innovation in the area of tissue markers.
La Commission craignait que le rachat, tel que notifié à l'origine, évince un futur concurrent crédible de Bard et risque par là même de limiter l'innovation dans le secteur des marqueurs tissulaires.